Physician profile
Charles Clark
NPI 1720425416
$453.04
in general payments reported to CMS, 2019-2025
12 companies · $272 in 2025
The $272 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $42.71 · 2021: $13.54 · 2024: $125 · 2025: $272.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $397.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $396.79 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mallinckrodt Hospital Products INC. | $160.61 | 2024-2025 | Acthar, Terlivaz |
| Otsuka America Pharmaceutical, INC. | $83.38 | 2024-2025 | Jynarque |
| Novartis Pharmaceuticals Corporation | $27.73 | 2025 | |
| E.R. Squibb & Sons, L.L.C. | $23.83 | 2020 | |
| Calliditas Therapeutics US INC. | $22.83 | 2024 | |
| Akebia Therapeutics INC | $22.76 | 2024 | Auryxia, Vafseo |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $21.26 | 2025 | Jynarque |
| Bioventus LLC | $21.00 | 2024 | Bonescalpel & Sonicone (O.R.) |
| Travere Therapeutics, INC. | $19.16 | 2025 | |
| Emd Serono, INC. | $18.88 | 2020 | |
| Aurinia Pharma U.S., INC. | $18.06 | 2024 | Lupkynis |
| Eisai INC. | $13.54 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Charles Clark listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.